VRCA · Verrica Pharmaceuticals Inc. · Analyst Estimates
$3.48
+0.01 (+0.29%)
At close · Oct 28
Return incl. dividend (before tax)
Q2 2026 earnings call transcript
Going-concern doubt
— flagged Aug 6, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on our current business plan and current capital resources, combined with the uncertainty regarding the availability of additional funding, we have concluded that there is substantial doubt regarding our ability to continue as a going concern within one year after the date these consolidated financial statements are issued.”View the 10-Q filed Aug 6, 2026
Market Cap
$59.27M
Shares
17.18M
Volume · Oct 28
22.37K
Avg daily vol (3M)
68.7K
Analyst Estimates
Compare analyst forecasts for Verrica Pharmaceuticals Inc. across metrics and forecast periods.
Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.
Compiled consensus
These figures are a compiled consensus of analyst forecasts, not a survey the company published itself. Every figure is the statistic the source states; averages are means, never medians.
Captured 2026-10-22 20:27 UTC · Publication dates shown per estimate · 8 metric / period groups
FY ending 2026-12-31
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-2.03
|
-1.88
|
-1.70
|
4
|
-1.97
|
-1.97
|
-2.01
|
-1.73
|
1
|
1
|
0
|
0
|
|
Revenue
USD
Publication date not stated |
22.60M
|
24.39M
|
26.60M
|
7
|
— | — | — | — | — | — | — | — |
FY ending 2027-12-31
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-1.50
|
-1.24
|
-0.85
|
4
|
-1.48
|
-1.48
|
-1.47
|
-1.24
|
1
|
1
|
0
|
0
|
|
Revenue
USD
Publication date not stated |
31.20M
|
39.22M
|
49.70M
|
7
|
— | — | — | — | — | — | — | — |
Q ending 2026-09-30
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-0.54
|
-0.49
|
-0.46
|
4
|
-0.52
|
-0.52
|
-0.54
|
-0.43
|
1
|
1
|
0
|
0
|
|
Revenue
USD
Publication date not stated |
5.30M
|
6.20M
|
7.50M
|
7
|
— | — | — | — | — | — | — | — |
Q ending 2026-12-31
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-0.51
|
-0.45
|
-0.36
|
4
|
-0.51
|
-0.51
|
-0.52
|
-0.42
|
1
|
1
|
0
|
0
|
|
Revenue
USD
Publication date not stated |
6.30M
|
7.31M
|
8.20M
|
7
|
— | — | — | — | — | — | — | — |